Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Treatment recommendations from the Eighth International Workshop on Waldenstroms Macroglobulinemia

(2016) V. Leblond et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

(2016) Mathias Rummel et al.   LANCET ONCOLOGY

Lenalidomide is safe and active in Waldenström macroglobulinemia

(2015) Guillemette Fouquet et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat Waldenstrom macroglobulinemia

(2015) S. P. Treon   BLOOD

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study

(2015) Jorge J. Castillo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

(2015) L. Simon et al.   HAEMATOLOGICA

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

(2015) Wolfram Poenisch et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

(2015) L. Simon et al.   HAEMATOLOGICA

Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus

(2014) M. A. Dimopoulos et al.   BLOOD

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

(2014) Y Cao et al.   LEUKEMIA

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

(2013) M. A. Dimopoulos et al.   BLOOD

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

(2013) Z. R. Hunter et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Challenges With Serum Protein Electrophoresis in Assessing Progression and Clinical Response in Patients With Waldenström Macroglobulinemia

(2013) Sacha N. Uljon et al.   Clinical Lymphoma Myeloma & Leukemia

Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia

(2013) Christina K. Tripsas et al.   Clinical Lymphoma Myeloma & Leukemia

Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia

(2013) Alessandra Tedeschi et al.   Clinical Lymphoma Myeloma & Leukemia

Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration

(2013) Steven P. Treon et al.   Clinical Lymphoma Myeloma & Leukemia

Schnitzler syndrome: an under-diagnosed clinical entity

(2013) T. Jain et al.   HAEMATOLOGICA

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification

(2013) B Paiva et al.   LEUKEMIA

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine as Therapy in Untreated and Relapsed Waldenström's Macroglobulinemia

(2012) D Laszlo et al.   Clinical Lymphoma Myeloma & Leukemia

Heterogeneity of Histological Transformation Events in Waldenström's Macroglobulinemia (WM) and Related Disorders

(2012) R G Owen et al.   Clinical Lymphoma Myeloma & Leukemia

Immunohistochemical Phenotyping of Plasma Cells in Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia is Comparable to Flow Cytometric Techniques

(2012) Matthew T. Howard et al.   Clinical Lymphoma Myeloma & Leukemia

Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   Clinical Lymphoma Myeloma & Leukemia

Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenström's Macroglobulinemia

(2012) Bryan T. Ciccarelli et al.   Clinical Lymphoma Myeloma & Leukemia

Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia

(2012) Steven P. Treon et al.   Clinical Lymphoma Myeloma & Leukemia

Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma

(2012) Véronique Leblond et al.   JOURNAL OF CLINICAL ONCOLOGY

Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005

(2012) Jeevan Sekhar et al.   LEUKEMIA & LYMPHOMA

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand

(2012) J. Tate et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Evidence-based focused review of management of hyperviscosity syndrome

(2011) M. J. Stone et al.   BLOOD

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

(2011) Steven P. Treon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia

(2011) Alessandra Tedeschi et al.   CANCER

Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia

(2011) B. Hivert et al.   HAEMATOLOGICA

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

(2010) Daniele Laszlo et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Charalampia Kyriakou et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia

(2010) Stefan Peinert et al.   LEUKEMIA & LYMPHOMA

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

(2010) Stephen M. Ansell et al.   MAYO CLINIC PROCEEDINGS

International prognostic scoring system for Waldenstrom macroglobulinemia

(2009) P. Morel et al.   BLOOD

How I treat Waldenstrom macroglobulinemia

(2009) S. P. Treon   BLOOD

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

(2009) Steven P. Treon et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

(2008) M. A. Dimopoulos et al.   HAEMATOLOGICA

Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs

(2008) Xavier Leleu et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

(2008) C Buske et al.   LEUKEMIA